肿瘤细胞治疗研究
ALL SOURCES
Recurrence score prediction formula based on immunohistochemistry and biopsy data to predict response to neoadjuvant chemotherapy in estrogen receptor
在61例患者中（中位年龄54岁），50%的患者临床肿瘤状态为2个肿瘤，40%的患者为淋巴结阳性疾病。
Clinicopathological Characterization of HER2-Low-Expressing Triple-Negative Breast Cancer: Distinct Features From HER2-Zero Subtype.
HER2-low与HER2-zero TNBC是生物学上不同的亚组。HER2-low肿瘤富集luminal AR样特征，而HER2-zero肿瘤表现出basal-like、高度增殖和免疫原性特征。尽管治疗结局无显著差异，这些发现提示HER2-low与HER2-zero TNBC可能需要不同的治疗策略。有必要开展前瞻性研究以验证这些发现并进一步探索个体化治疗策略。
Human Epidermal Growth Factor Receptor 2 Positive Advanced Gastric or Esophagogastric Adenocarcinoma: Reflecting on the Past to Gain a New Insights.
曲妥珠单抗作为 HER2 阳性 AGC 的标准治疗已长达十年，随后，抗体偶联药物（ADC）德曲妥珠单抗问世，并展现出令人瞩目的缓解。
Anti-HER2 Cancer-Specific mAb, H(2)Mab-250-hG(1), Possesses Higher Complement-Dependent Cytotoxicity than Trastuzumab.
这些结果表明，ADCC和CDC活性对H 2 Mab-250-hG 1和trastuzumab的抗肿瘤效果有不同的贡献，并为H 2 Mab-250-hG 1针对HER2阳性肿瘤的临床开发指明了未来方向。
Trastuzumab, a monoclonal anti-HER2 antibody modulates cytotoxicity against cholangiocarcinoma via multiple mechanisms.
胆管癌（CCA）是一种侵袭性强且致命的癌症。
The Future of HER2-Targeted Treatment for Osteosarcoma: Lessons from the Negative Trastuzumab Deruxtecan Results.
约 30% 的骨肉瘤患者存在 HER2 过表达，针对骨肉瘤的 HER2 靶向治疗以及 HER2 的预后和/或预测价值也已被研究。
Association between tumor-infiltrating lymphocytes and oncotype DX estrogen receptor, progesterone receptor, and human epidermal growth factor recepto
在 HR+/HER2- 乳腺癌中，HER2 mRNA 表达较低的肿瘤表现出更高的淋巴细胞浸润，提示存在一个独特的免疫活跃亚群。
Clinical characteristics and prognostic impact of HER2-ultralow breast cancer and tumor-infiltrating lymphocytes (TILs).
HER2-ultralow肿瘤代表一个独特的亚组，其特征为激素受体阳性率更高，而HER2-null肿瘤与更年轻年龄、更高的TIL密度和更差的生存相关。这些发现强调了细化HER2阴性亚分类以区分HER2-ultralow的临床意义，同时承认样本量和回顾性设计的局限性。
Mechanisms of resistance to antibody-drug conjugates in cancers.
近年来，随着分子靶向药物、单克隆抗体、免疫检查点抑制剂、双特异性抗体和CAR-T 细胞疗法等多种治疗模式的出现，癌症治疗取得了巨大进展。
An increase in tumor-infiltrating lymphocytes after treatment is significantly associated with a poor response to neoadjuvant endocrine therapy for es
NET后TILs增加与NET反应不佳显著相关。鉴于NET后TILs增加的患者中FOXP3+ T细胞计数增加，而中性粒细胞计数并未减少，推测免疫抑制微环境的诱导在疗效较差中发挥了作用。这些数据可能部分表明免疫反应参与内分泌治疗的疗效。
MEMBER ACCOUNT
登录成功会直接打开下一页。
